Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Marie Terroir-Cassou-Mounat
Observed names:
M. Terroir,
M. Terroir Cassou Mouna,
M. Terroir-Cassou-Mounat,
Marie Terroir,
Terroir-Cassou-Mounat, Marie
Institutions:
Institut universitaire du cancer de Toulouse Oncopole,
Université de Toulouse
Observed institutions:
Université Paris-Saclay,
Institut Gustave Roussy,
Institut universitaire du cancer de Toulouse Oncopole,
Institut Claudius Regaud,
Université de Toulouse
ORCID:
0000-0003-1395-8472
Observed ORCID:
0000-0003-1395-8472
OpenAlex ID:
A5027733848
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
2020
·
Etienne Garin
, Lambros Tselikas
, et al.
·
The Lancet. Gastroenterology & hepatology
·
670
PDF
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2023
·
Sophie Leboulleux
, Christine Do Cao
, et al.
·
Clinical Cancer Research
·
128
PDF
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131 I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
2023
·
Sophie Leboulleux
, Daniele Benisvy
, et al.
·
Thyroid
·
49
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
2020
·
Dana M. Hartl
, Joanne Guerlain
, et al.
·
Cancers
·
41
PDF
MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)
2021
·
Sophie Leboulleux
, Christine Do Cao
, et al.
·
Journal of the Endocrine Society
·
34
PDF
Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01).
2020
·
Etienne Garin
, Lambros Tzelikas
, et al.
·
Journal of Clinical Oncology
·
32
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations
2018
·
Christophe Willekens
, Aline Renneville
, et al.
·
Leukemia
·
27
Diagnostic imaging of salivary gland cancers: REFCOR recommendations by the formal consensus method
2023
·
A. Varoquaux
, N. Fakhry
, et al.
·
European Annals of Otorhinolaryngology Head and Neck Diseases
·
22
RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
2023
·
Marie Terroir
, Chloé Lamesa
, et al.
·
Pharmaceuticals
·
10
PDF
Post-Shingles Granulomatous Dermatosis Related to Anti-Programmed Cell Death 1
2019
·
Tarek Assi
, Alina Danu
, et al.
·
Immunotherapy
·
10
Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma
2015
·
Christophe Willekens
, Jean-Baptiste Micol
, et al.
·
Blood
·
6
Deep learning-enhanced digital-BGO versus TOF PET/CT: comparative assessment of detection, quantitation, and overall image quality
2025
·
Quentin Maronnier
, Thibaut Cassou-Mounat
, et al.
·
EJNMMI Physics
·
3
Insertion of synthetic lesions on patient data: a method for evaluating clinical performance differences between PET systems
2024
·
Quentin Maronnier
, Nesrine Robaine
, et al.
·
EJNMMI Physics
·
3
PDF
Rare Immuno-Induced Keratoacanthomas Showed on 18F-FDG PET/CT in a Metastatic Melanoma Patient
2025
·
Naia Oillarburu
, Cécile Pages
, et al.
·
Clinical Nuclear Medicine
·
2
Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
2024
·
Sophie Leboulleux
, Christine Do Cao
, et al.
·
1
Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2023
·
Sophie Leboulleux
, Christine Do Cao
, et al.
·
1
Optimisation des temps d’acquisition avec un TEP-TDM haute sensibilité de dernière génération
2023
·
Q. Maronnier
, T. Cassou Mounat
, et al.
·
Médecine Nucléaire
·
1
Prospective study on the [18F]FDOPA PET/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery
2026
·
Marie Terroir
, Amelie Lusque
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
Comparaison en vie réelle entre la TEP-TDM au 18F-FDG et la TDM pour le suivi des patients avec mélanome cutané traités par immunothérapie adjuvante
2026
·
A. Bauduer
, V. Sibaud
, et al.
·
Médecine Nucléaire
Supplementary Table S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2025
·
Sophie Leboulleux
, Christine Do Cao
, et al.
Supplementary Figure S1 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2025
·
Sophie Leboulleux
, Christine Do Cao
, et al.
Supplementary Figure S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2025
·
Sophie Leboulleux
, Christine Do Cao
, et al.
Supplementary Figure S3 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2025
·
Sophie Leboulleux
, Christine Do Cao
, et al.
Supplementary Table S3 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2025
·
Sophie Leboulleux
, Christine Do Cao
, et al.
Supplementary Table S4 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
2025
·
Sophie Leboulleux
, Christine Do Cao
, et al.
Show more works
View as search
Works count:
88
Citation count:
1,710
H-index:
10
I10-index:
11
Year
Topic
Type